Tuesday, November 08, 2022 8:43:08 PM
Please correct me if I'm wrong, I believe that when the trial resumed it was agreed that all patients would receive the DCVax-L. Essentially at that time the regulators abandoned the control group and PFS as the primary goal. It took years to formalize what went on here, but in the end everything is falling into place including the use of historical data rather than control groups.
I certainly don't know, but I believe that in the future few trials for fatal disease will be done with control groups, new trials will allow all patients to get the experimental products. I believe this will make getting into clinical trials more desirable and have less patients dropping out when they determine they're not getting the experimental drug. Have no doubt, some patients can get their personal physicians to run tests that can almost definitely say whether they're getting the experimental treatment, or not.
This change is not being brought about by NWBO alone, but our trial certainly is helping to move the regulators in that way.
Gary
I certainly don't know, but I believe that in the future few trials for fatal disease will be done with control groups, new trials will allow all patients to get the experimental products. I believe this will make getting into clinical trials more desirable and have less patients dropping out when they determine they're not getting the experimental drug. Have no doubt, some patients can get their personal physicians to run tests that can almost definitely say whether they're getting the experimental treatment, or not.
This change is not being brought about by NWBO alone, but our trial certainly is helping to move the regulators in that way.
Gary
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
